Honor Health Research Institute
Honor Health Research Institute
Scottsdale, Arizona, United States17 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Dabrafenib and/or Trametinib Rollover Study | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, epithelial neoplasm, glioma, lung disorder, lung neoplasm, malignant glioma, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, neuroepithelial neoplasm, non-small cell lung carcinoma, primitive neuroectodermal tumor, respiratory system disorder, respiratory tract neoplasm, skin disorder, skin neoplasm | Recruiting | Phase 4 | 2026-10-09 | NCT03340506 | |
| AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, cervical adenocarcinoma, cervical adenosquamous carcinoma, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, gastric adenocarcinoma, intestinal disorder, lung disorder, lung neoplasm, neoplasm, rectal disorder, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinoma, vulvar adenocarcinoma | Recruiting | Phase 1 | 2026-10-05 | NCT07454642 | |
| Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic adenocarcinoma, pancreatic adenosquamous carcinoma, pancreatic neoplasm | Recruiting | Phase 3 | 2026-10-02 | NCT07491445 | |
| A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis | Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, autoimmune disease, autoimmune disorder of the nervous system, immune system disorder, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndrome | Active, not recruiting | Phase 3 | 2026-09-28 | NCT06744920 | |
| Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer | Carcinoma, Ductal, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Ductal, Lobular, and Medullary, Skin and Connective Tissue Diseases, adenocarcinoma, breast disorder, breast ductal adenocarcinoma, breast neoplasm, carcinoma, epithelial neoplasm, neoplasm, skin disorder | Recruiting | Not applicable | 2026-09-23 | NCT07214532 | |
| Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Recruiting | Phase 2 / Phase 3 | 2026-09-22 | NCT06780670 | |
| Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Uveal Neoplasms, eye disorder, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, ocular cancer, primitive neuroectodermal tumor, uveal disorder, uveal melanoma | Recruiting | Phase 3 | 2026-09-15 | NCT07804186 | |
| A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors Including Biliary Tract Cancer | Biliary Tract Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, biliary tract cancer, biliary tract disorder, neoplasm | Active, not recruiting | Phase 1 | 2026-09-02 | NCT03440450 | |
| SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm, susceptibility to familial cutaneous melanoma | Recruiting | Phase 3 | 2026-08-18 | NCT06743126 | |
| A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG. | Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, autoimmune disease, autoimmune disorder of the nervous system, immune system disorder, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndrome | Active, not recruiting | Phase 3 | 2026-08-12 | NCT06517758 | |
| Pancreatic Cancer Early Detection Consortium | Cysts, Digestive System Diseases, Digestive System Neoplasms, Disease Attributes, Neoplasms by Site, Pancreatic Cyst, Pathologic Processes, Pathological Conditions, Signs and Symptoms, disease susceptibility, endocrine system disorder, inherited disease susceptibility, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic ductal adenocarcinoma, pancreatic neoplasm | Recruiting | Not stated | 2026-07-22 | NCT04970056 | |
| Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors | Advanced Solid Tumors | Recruiting | Phase 1 / Phase 2 | 2026-05-06 | NCT06819735 | |
| Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Site, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder | Active, not recruiting | Phase 1 | 2026-04-09 | NCT04794699 | |
| Long-Term Follow-up Study | B-cell neoplasm, B-cell non-Hodgkin lymphoma, Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, acute myeloid leukemia, cardiovascular disorder, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, monoclonal gammopathy, myeloid leukemia, neoplasm, non-Hodgkin lymphoma, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Enrolling by invitation | Not stated | 2026-03-12 | NCT05332054 | |
| Study of Oral MRT-2359 in Selected Cancer Patients | B-cell neoplasm, Genital Diseases, Hemic and Lymphatic Diseases, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, lung disorder, lung neoplasm, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, male reproductive organ cancer, male reproductive system disorder, neoplasm, non-small cell lung carcinoma, prostate cancer, prostate disorder, respiratory system disorder, respiratory tract neoplasm, skin disorder, small cell lung carcinoma | Active, not recruiting | Phase 1 / Phase 2 | 2026-03-03 | NCT05546268 | |
| Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors | Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, neoplasm | Recruiting | Phase 1 | 2025-12-19 | NCT05270213 | |
| A Study of NDI 1150-101 in Patients With Solid Tumors | Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, bronchial neoplasm, bronchogenic carcinoma, carcinoma, central nervous system malformation, epithelial neoplasm, hereditary disease, hereditary sensory and autonomic neuropathy, inherited neurodegenerative disorder, kidney cancer, kidney disorder, lung disorder, lung neoplasm, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, non-small cell lung carcinoma, peripheral nervous system disorder, polyneuropathy, renal cell carcinoma, respiratory system disorder, respiratory tract neoplasm, urinary system disorder | Active, not recruiting | Phase 1 / Phase 2 | 2024-11-25 | NCT05128487 |